Find a Doctor

Antoine Italiano

Institut Bergonié
Male

Bio


Antoine Italiano is in Bordeaux, France. They have been an author on 342 peer reviewed articles and participated in 22 clinical trials in the past 15 years.

Contact

Bordeaux, FR

Latest Advances


Latest Advance
Study
  • Condition: Epithelioid Sarcoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Tazemetostat
  • Number of Patients: 62
  • Published —
This study evaluated the safety and effectiveness of Tazemetostat, an oral selective EZH2 inhibitor, in patients with epithelioid sarcoma.
Latest Advance
Study
  • Condition: Germline BRCA-Mutated Metastatic Breast Cancer
  • Journal: The Lancet. Oncology
  • Treatment Used: Olaparib and Durvalumab
  • Number of Patients: 34
  • Published —
The purpose of the study was to assess the safety and activity of Olaparib in combination with Durvalumab in patients with germline BRCA1-mutated or BRCA1-mutated metastatic breast cancer.
Latest Advance
Study
  • Condition: Patients with Advanced Ewing Sarcoma or Osteosarcoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Cabozantinib
  • Number of Patients: 90
  • Published —
This study investigated the activity of cabozantinib, an inhibitor of MET and VEGFR2, in patients with advanced Ewing sarcoma and osteosarcoma.
Latest Advance
Study
  • Condition: Sarcoma
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Surgery in Reference Center
  • Number of Patients: 35784
  • Published —
This study investigated the impact of surgery in a reference center on the survival of patients with sarcoma.
Latest Advance
Study
  • Condition: Non-Adipocytic Sarcoma
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Regorafenib after Chemotherapy and Pazopanib
  • Number of Patients: 37
  • Published —
This study tested the safety and efficacy of using regorafenib in patients that already underwent chemotherapy with pazopanib to treat their non-adipocytic sarcoma.
Latest Advance
Study
  • Condition: HER2-Positive Metastatic Breast Cancer
  • Journal: Breast cancer research : BCR
  • Treatment Used: Epertinib plus Trastuzumab with or without Chemotherapy
  • Number of Patients: 23
  • Published —
In this study, researchers compared the outcomes of epertinib plus trastuzumab with or without chemotherapy for the treatment of HER2-positive metastatic breast cancer.
Latest Advance
Study
  • Condition: Advanced Tenosynovial Giant Cell Tumor (TGCT)
  • Journal: Scientific reports
  • Treatment Used: Imatinib Mesylate (IM)
  • Number of Patients: 62
  • Published —
This study investigated the long term effects of imatinib mesylate (IM) in tenosynovial giant cell tumors (TGCT).
Latest Advance
Study
  • Condition: Extraskeletal Myxoid Chondrosarcoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Pazopanib
  • Number of Patients: 23
  • Published —
This study investigated the activity of pazopanib in patients with advanced extraskeletal myxoid chondrosarcoma.
Latest Advance
Study
  • Condition: Desmoid Tumors
  • Journal: The Lancet. Oncology
  • Treatment Used: Pazopanib vs. Methotrexate-Vinblastine
  • Number of Patients: 72
  • Published —
This study aimed to compare pazopanib with methotrexate-vinblastine combination therapy in patients with desmoid tumors.
Latest Advance
Study
  • Condition: Adult Patients with Osteosarcoma
  • Journal: International journal of cancer
  • Treatment Used: API-AI Based Regimen
  • Number of Patients: 106
  • Published —
This study reported the prespecified subgroup analysis of the outcome of patients treated with doxorubicin-cisplatin-ifosfamide-based regimen (API-AI).
Latest Advance
Study
  • Condition: Abdominal Desmoplastic Small Round Cell Tumor
  • Journal: Surgical oncology
  • Treatment Used: Systemic chemotherapy, complete cytoreductive surgery and whole abdomino-pelvic radiation therapy
  • Number of Patients: 100
  • Published —
The study researched the attempts at curing abdominal desmoplastic small round cell tumor.
Latest Advance
Study
  • Condition: Advanced or Refractory Solid Tumors
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor
  • Number of Patients: 187
  • Published —
This study reported results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor in the treatment of advanced or refractory solid tumors.
Latest Advance
Study
  • Condition: Patients with Advanced Gastrointestinal Stromal Tumors (GISTs) Refractory to Imatinib and Sunitinib
  • Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
  • Treatment Used: Palbociclib
  • Number of Patients: 71
  • Published —
This study assessed the safety and effectiveness of palbociclib in patients with advanced gastrointestinal stromal tumors (GISTs) bearing CDKN2A gene loss.
Latest Advance
Study
  • Condition: Advanced Cervical Cancer
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Pembrolizumab
  • Number of Patients: 98
  • Published —
In this study, researchers evaluated the safety and effectiveness of pembrolizumab for the treatment of previously treated advanced cervical cancer.
Latest Advance
Study
  • Condition: Localized High Grade Endometrial Stromal Sarcoma and Localized Undifferentiated Uterine Sarcoma
  • Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • Treatment Used: Surgical Resection and Adjuvant Radiotherapy and Chemotherapy
  • Number of Patients: 39
  • Published —
This study analyzed patients with localized high grade endometrial stromal sarcoma and undifferentiated uterine sarcomas (stages I-III) and their treatments.
Latest Advance
Study
  • Condition: Advanced Malignant and Dedifferentiated Solitary Fibrous Tumor
  • Journal: The Lancet. Oncology
  • Treatment Used: Pazopanib
  • Number of Patients: 36
  • Published —
This trial assessed the activity of pazopanib in patients with malignant or dedifferentiated solitary fibrous tumor.
Latest Advance
Study
  • Condition: Adult Patients with Metastatic Osteosarcoma
  • Journal: The Lancet. Oncology
  • Treatment Used: Regorafenib
  • Number of Patients: 43
  • Published —
This study assessed the effectiveness and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas.
Latest Advance
Study
  • Condition: Metastatic progesterone receptor-expressing cancers
  • Journal: PloS one
  • Treatment Used: Onapristone
  • Number of Patients: 52
  • Published —
This study evaluated the effects of onapristone in patients with metastatic progesterone receptor-expressing cancers.
Latest Advance
Study
  • Condition: Metastatic gastrointestinal stromal tumors
  • Journal: PloS one
  • Treatment Used: Imatinib
  • Number of Patients: 151
  • Published —
This study evaluated imatinib for the treatment of metastatic gastrointestinal stromal tumors.
Latest Advance
Study
  • Condition: Solid tumors
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Epertinib
  • Number of Patients: 76
  • Published —
This study assessed the safety and efficacy of epertinib in patients with solid tumours.
Latest Advance
Study
  • Condition: Non-adipocytic soft tissue sarcoma
  • Journal: European journal of cancer (Oxford, England : 1990)
  • Treatment Used: Regorafenib
  • Number of Patients: 139
  • Published —
This study evaluated regorafenib in patients with advanced non-adipocytic soft tissue sarcoma.
Latest Advance
Study
  • Condition: Myofibroblastic Tumors
  • Journal: The Lancet. Respiratory medicine
  • Treatment Used: Crizotinib
  • Number of Patients: 19
  • Published —
In this study, researchers evaluated the safety and effectiveness of crizotinib for the treatment of advanced, inoperable inflammatory myofibroblastic tumors.
Latest Advance
Study
  • Condition: B-cell non-Hodgkin lymphoma and advanced solid tumours
  • Journal: The Lancet. Oncology
  • Treatment Used: Tazemetostat
  • Number of Patients: 64
  • Published —
This study aimed to investigate the safety, clinical activity, pharmacokinetics, and pharmacodynamics of tazemetostat, a first-in-class selective inhibitor of EZH2.
Latest Advance
Study
  • Condition: Locally Advanced Pigmented Villonodular Synovitis
  • Journal: The Lancet. Oncology
  • Treatment Used: Nilotinib
  • Number of Patients: 56
  • Published —
This study tested the safety and efficacy of using nilotinib to treat patients with diffuse-type giant cell tumors known as locally advanced pigmented villonodular synovitis.
Latest Advance
Study
  • Condition: Alveolar Soft Part Sarcoma (ASPS) with Rearrangement of Transcription Factor E3 (TFE3)
  • Journal: Annals of oncology : official journal of the European Society for Medical Oncology
  • Treatment Used: Crizotinib
  • Number of Patients: 48
  • Published —
This study assessed the efficacy and safety of the MET tyrosine kinase inhibitor crizotinib in patients with advanced or metastatic alveolar soft part sarcoma (ASPS).

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Genetic
  • Participants: 332
  • Start Date: September 4, 2020
Circulating DNA to Improve Outcome of Oncology PatiEnt: A Randomized Study - COPE Study
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 33
  • Start Date: March 4, 2020
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 34
  • Start Date: January 22, 2020
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Drug
  • Participants: 200
  • Start Date: January 6, 2020
Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 126
  • Start Date: May 15, 2019
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 300
  • Start Date: March 12, 2019
A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 351
  • Start Date: February 14, 2019
Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 180
  • Start Date: January 31, 2019
A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1/Phase 2
  • Intervention Type: Drug
  • Participants: 362
  • Start Date: May 4, 2018
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Intervention Type: Diagnostic Test, Genetic
  • Participants: 1000
  • Start Date: May 3, 2017
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Diagnostic Test
  • Participants: 370
  • Start Date: April 1, 2017
SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 1
  • Intervention Type: Drug
  • Participants: 873
  • Start Date: June 23, 2016
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 250
  • Start Date: December 22, 2015
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 227
  • Start Date: June 2015
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 2
  • Intervention Type: Drug
  • Participants: 132
  • Start Date: September 2014
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

All Publications
View All


Publication
Study
  • Journal: Expert opinion on pharmacotherapy
  • Published —
New insights into the clinical management of advanced gastrointestinal stromal tumors.

Contact

Bordeaux, FR

Insurance

Contact them to find out if they accept your insurance plan.